Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. The identification of novel targets for cancer treatment is an area of intense work that has led Bcl-2 over-expression to be proposed as one of the hallmarks of cancer and Bcl-2 inhibition as a promising...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2018-12, Vol.19 (12), p.3950
Hauptverfasser:	García-Aranda, Marilina, Pérez-Ruiz, Elisabet, Redondo, Maximino
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Apoptosis Bcl-2 protein Cancer Cancer therapies Cell death Cytotoxicity Disease Drug Resistance, Neoplasm Humans Immune system Immunotherapy Ligands Lymphocytes Models, Biological Neoplasms - immunology Neoplasms - pathology Neoplasms - therapy Overexpression Proteins Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors Proto-Oncogene Proteins c-bcl-2 - metabolism Review Signal transduction Tumor necrosis factor-TNF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. The identification of novel targets for cancer treatment is an area of intense work that has led Bcl-2 over-expression to be proposed as one of the hallmarks of cancer and Bcl-2 inhibition as a promising strategy for cancer treatment. In this review, we describe the different pathways related to programmed cell death, the role of Bcl-2 family members in apoptosis resistance to anti-cancer treatments, and the potential utility of Bcl-2 inhibitors to overcome resistance to chemo- and immunotherapy.
ISSN:	1422-0067 1661-6596 1422-0067
DOI:	10.3390/ijms19123950